Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 4Infections 3Thyroid Nodule 2Neoplasms, Plasma Cell 2Lymphoma, Follicular 2Lymphoma 2Leukemia 2Febrile Neutropenia 2Urinary Bladder Neoplasms 1Surgical Wound Infection 1Sepsis 1Respiratory Sounds 1Prostatic Neoplasms 1Lymphoma, Non-Hodgkin 1Glioblastoma 1Emergencies 1Diverticulitis 1Cystectomy 1Brain Neoplasms 1Astrocytoma 1Asthma 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × Amoxicillin-Potassium Clavulanate Combination × Clear all
NCT01967758 2018-08-17

Phase I Study of Safety and Immunogenicity of ADU-623

Providence Health & Services

Phase 1 Completed
11 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡